Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

EP, Mamounas; J, Bryant; B, Lembersky; L, Fehrenbacher; SM, Sedlacek; B, Fisher; DL, Wickerham; G, Yothers; A, Soran; N, Wolmark

doi:10.1200/jco.2005.10.517

Public

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

Shared by NobleBlocks on May 16, 2005 • 12:00 AM UTC

Authors:

Mamounas EP

Bryant J

Lembersky B

Abstract

Purpose The primary aim of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 was to determine whether four cycles of adjuvant paclitaxel (PTX) after four cycles of adjuvant doxorubicin/cyclophosphamide (AC) will prolong disease-free survival (DFS) and overall survival (OS) compared wi...

Discussions